Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin America

Helio S Sader; Cecilia G Carvalhaes; Jennifer M Streit; Mariana Castanheira; Robert K Flamm

doi:10.1016/j.ijid.2019.11.006

Back

Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin America

Journal article

Open access

Peer reviewed

Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin America

Helio S Sader, Cecilia G Carvalhaes, Jennifer M Streit, Mariana Castanheira and Robert K Flamm

International journal of infectious diseases, Vol.91, pp.32-37

02/2020

DOI: 10.1016/j.ijid.2019.11.006

PMID: 31715325

Files and links (1)

url

https://doi.org/10.1016/j.ijid.2019.11.006View

Published (Version of record) Open Access

Abstract

To evaluate the antimicrobial activities of cefoperazone-sulbactam and comparator agents tested against a large collection of clinical isolates of Gram-negative organisms. A total of 19545 Gram-negative organisms were collected from medical centers located in western Europe (W-EUR; n=10626), eastern Europe and the Mediterranean region (E-EUR; n=4029), the Asia-Pacific region (APAC; n=2491), and Latin America (LATAM; n=2399) in 2015-2016 and susceptibility tested by reference broth microdilution methods. Overall, 91.5% of Enterobacterales were susceptible (≤16mg/L) to cefoperazone-sulbactam, with susceptibility rates ranging from 82.0% (E-EUR) to 94.4% (W-EUR); overall susceptibility to cefoperazone-sulbactam, piperacillin-tazobactam, imipenem, and ceftriaxone was 91.5%, 85.4%, 90.5%, and 72.1%, respectively. Among Pseudomonas aeruginosa isolates, cefoperazone-sulbactam susceptibility rates were higher in W-EUR, APAC, and LATAM (83.0-84.6%) compared to E-EUR (59.5%). Susceptibility to piperacillin-tazobactam, imipenem, and ceftazidime was 78.3%, 76.2%, and 82.0% in W-EUR; 52.3%, 43.5%, and 57.4% in E-EUR; 83.5%, 80.1%, and 84.5% in APAC; and 81.5%, 72.8%, and 83.0% in LATAM, respectively. Acinetobacter spp. susceptibility rates varied from 43.0% in E-EUR to 75.8% in LATAM (53.2% overall) for cefoperazone-sulbactam and from 19.8% in E-EUR to 40.2% in W-EUR (26.4% overall) for imipenem. Susceptibility rates varied widely among geographic regions and were generally lowest in E-EUR. Based on the potency and activity spectrum, cefoperazone-sulbactam remains among the most active compounds in vitro at published breakpoints.

Acinetobacter - drug effects

Acinetobacter - isolation & purification

Anti-Bacterial Agents - pharmacology

Asia

Cefoperazone - pharmacology

Europe

Gammaproteobacteria - drug effects

Gammaproteobacteria - isolation & purification

Gram-Negative Bacteria - drug effects

Gram-Negative Bacteria - isolation & purification

Humans

Latin America

Pseudomonas aeruginosa - drug effects

Pseudomonas aeruginosa - isolation & purification

Sulbactam - pharmacology

Details

Title: Subtitle: Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin America
Creators: Helio S Sader - JMI Laboratories
Cecilia G Carvalhaes - JMI Laboratories
Jennifer M Streit - JMI Laboratories
Mariana Castanheira - JMI Laboratories
Robert K Flamm - JMI Laboratories
Resource Type: Journal article
Publication Details: International journal of infectious diseases, Vol.91, pp.32-37
DOI: 10.1016/j.ijid.2019.11.006
PMID: 31715325
NLM abbreviation: Int J Infect Dis
ISSN: 1201-9712
eISSN: 1878-3511
Grant note: DOI: 10.13039/100004319, name: Pfizer
Language: English
Date published: 02/2020
Academic Unit: Pathology
Record Identifier: 9984185179402771

Metrics

18 Record Views

38 Times Cited - Web of Science